RecruitingPhase 2NCT06773962

A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of TB006 in Participants With Parkinson's Disease

Sponsor

TrueBinding, Inc.

Enrollment

62 participants

Start Date

Mar 20, 2025

Study Type

INTERVENTIONAL

Conditions

Parkinson's Disease (PD)

Summary

The primary objectives of this study are to assess the efficacy of TB006 in improving motor function and to assess the safety of TB006 in participants with Parkinson's Disease (PD).

Eligibility

Min Age: 50 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called TB006 in people with early-stage Parkinson's disease. Parkinson's is a brain condition that gradually affects movement and balance. Researchers want to see if TB006 is safe and whether it can slow the disease's progression in the early stages. **You may be eligible if...** - You have been diagnosed with Parkinson's disease within the past 5 years - Your symptoms are mild and in the early stage - Your motor (movement) symptoms improve with levodopa medication - You are currently taking immediate-release levodopa-carbidopa or benserazide - You are in generally good health with no active cancer (or cancer in remission for 10+ years) **You may NOT be eligible if...** - Your Parkinson's diagnosis is more than 5 years old - You have moderate or advanced Parkinson's symptoms - You have significant health conditions or are not on levodopa - You have active cancer (other than fully removed skin cancer) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTB006

IV infusion.

DRUGPlacebo

IV infusion.

Locations(14)

Parkinson's Research Centers of America - Orange County

Aliso Viejo, California, United States

Parkinson's Research Centers of America - Palo Alto

Palo Alto, California, United States

CenExel Rocky Mountain Clinical Research

Englewood, Colorado, United States

Parkinson's Disease and Movement Disorders Center of Boca Raton

Boca Raton, Florida, United States

University of Miami

Miami, Florida, United States

University of South Florida Parkinson's and Movement Disorders Center

Tampa, Florida, United States

Consultants in Neurology, Ltd

Northbrook, Illinois, United States

Josephson Wallack Munshower Neurology - Southeast

Indianapolis, Indiana, United States

University of Kansas Medical Center

Kansas City, Kansas, United States

Quest Research Institute

Farmington Hills, Michigan, United States

Parkinson's Research Centers of America - Long Island

Commack, New York, United States

NYU Langone Health

Patchogue, New York, United States

Oregon Health & Science University

Portland, Oregon, United States

Central Texas Neurology Consultants

Round Rock, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06773962

Related Trials

A Study of Buntanetap in Participants With PD

NCT0728478427 locations

A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease

NCT073228871 location

Electrophysiology-based DBS Programming for PD

NCT073487051 location

Effects of the Stimulation Site of tsMS With TMS on Functional Mobility in Individuals With Parkinson's Disease

NCT074880261 location

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT073102641 location